Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Monoclonal Antibody to PACAP for Migraine Prevention.
Ashina M, Phul R, Khodaie M, Löf E, Florea I. Ashina M, et al. Among authors: phul r. N Engl J Med. 2024 Sep 5;391(9):800-809. doi: 10.1056/NEJMoa2314577. N Engl J Med. 2024. PMID: 39231342 Clinical Trial.
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P. Ashina M, et al. Among authors: phul r. Cephalalgia. 2023 May;43(5):3331024231170807. doi: 10.1177/03331024231170807. Cephalalgia. 2023. PMID: 37125484 Free article. Clinical Trial.
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Barbanti P, et al. Among authors: phul r. J Headache Pain. 2022 Dec 2;23(1):153. doi: 10.1186/s10194-022-01521-w. J Headache Pain. 2022. PMID: 36460983 Free PMC article. Clinical Trial.
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Ashina M, et al. Among authors: phul r. Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5. Lancet Neurol. 2022. PMID: 35716692 Clinical Trial.
16 results